Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2025-02-14 09:31 am Purchase |
2024-12-31 | 13G | Adaptimmune Therapeutics plc ADAP |
Two Seas Capital LP | 89,010,876 5.800% |
89,010,876 (New Position) |
Filing History |
| 2025-02-12 10:25 am Sale |
2024-12-31 | 13G | Adaptimmune Therapeutics plc ADAP |
BAILLIE GIFFORD & CO | 70,914,570 4.600% |
-24,558,270 (-25.72%) |
Filing History |
| 2025-02-11 4:40 pm Purchase |
2024-12-31 | 13G | Adaptimmune Therapeutics plc ADAP |
Long Focus Capital Management LLC | 20,494,393 8.000% |
8,407,478 (+69.56%) |
Filing History |
| 2025-01-08 10:30 am Sale |
2024-12-31 | 13G | Adaptimmune Therapeutics plc ADAP |
Matrix Capital Management Company, LP | 0 0.000% |
-135,000,000 (Position Closed) |
Filing History |
| 2024-12-05 5:17 pm Sale |
2024-11-30 | 13G | Adaptimmune Therapeutics plc ADAP |
Matrix Capital Management Company, LP | 135,000,000 8.800% |
-91,089,090 (-40.29%) |
Filing History |
| 2024-11-13 09:04 am Sale |
2024-09-30 | 13G | Adaptimmune Therapeutics plc ADAP |
Matrix Capital Management Company, LP | 226,089,090 14.730% |
-7,756,020 (-3.32%) |
Filing History |
| 2024-04-02 8:38 pm Unchanged |
2024-04-01 | 13D | Adaptimmune Therapeutics plc ADAP |
New Enterprise Associates 14, L.P. | 102,478,672 6.700% |
0 (Unchanged) |
Filing History |
| 2024-03-26 11:59 am Purchase |
2024-03-08 | 13G | Adaptimmune Therapeutics plc ADAP |
EcoR1 Capital LLC | 164,424,420 10.700% |
51,000,000 (+44.96%) |
Filing History |
| 2024-02-14 5:04 pm Purchase |
2023-12-31 | 13G | Adaptimmune Therapeutics plc ADAP |
Long Focus Capital Management LLC | 12,086,915 5.300% |
774,568 (+6.85%) |
Filing History |
| 2024-02-14 4:21 pm Purchase |
2023-12-31 | 13G | Adaptimmune Therapeutics plc ADAP |
Baker Bros. Advisors LP | 65,815,692 4.800% |
6,830,430 (+11.58%) |
Filing History |
| 2024-01-30 5:26 pm Purchase |
2024-01-30 | 13G | Adaptimmune Therapeutics plc ADAP |
EcoR1 Capital LLC | 113,424,420 7.700% |
113,424,420 (New Position) |
Filing History |
| 2024-01-29 11:52 am Sale |
2023-12-29 | 13G | Adaptimmune Therapeutics plc ADAP |
BAILLIE GIFFORD & CO | 95,472,840 7.010% |
-7,546,794 (-7.33%) |
Filing History |
| 2023-11-08 12:59 pm Purchase |
2023-10-31 | 13G | Adaptimmune Therapeutics plc ADAP |
Long Focus Capital Management LLC | 11,312,347 5.000% |
11,312,347 (New Position) |
Filing History |
| 2023-07-10 4:15 pm Unchanged |
2023-06-30 | 13G | Adaptimmune Therapeutics plc ADAP |
Matrix Capital Management Company, LP | 233,845,110 17.290% |
0 (Unchanged) |
Filing History |
| 2023-03-30 5:13 pm Purchase |
2023-03-05 | 13D | Adaptimmune Therapeutics plc ADAP |
New Enterprise Associates 14, L.P. | 102,478,672 10.300% |
3,556,804 (+3.60%) |
Filing History |
| 2023-02-14 4:06 pm Sale |
2022-12-31 | 13G | Adaptimmune Therapeutics plc ADAP |
PFM Health Sciences, LP | 29,061,060 3.000% |
-25,597,620 (-46.83%) |
Filing History |
| 2023-02-13 2:49 pm Sale |
2023-02-14 | 13G | Adaptimmune Therapeutics plc ADAP |
Capital World Investors | 0 0.000% |
-48,016,200 (Position Closed) |
Filing History |
| 2023-01-18 06:41 am Purchase |
2022-12-30 | 13G | Adaptimmune Therapeutics plc ADAP |
BAILLIE GIFFORD & CO | 103,019,634 10.480% |
401,082 (+0.39%) |
Filing History |
| 2022-12-02 07:33 am Purchase |
2022-11-30 | 13G | Adaptimmune Therapeutics plc ADAP |
BAILLIE GIFFORD & CO | 102,618,552 10.440% |
20,080,440 (+24.33%) |
Filing History |
| 2022-05-09 4:51 pm Purchase |
2022-04-28 | 13G | Adaptimmune Therapeutics plc ADAP |
PFM Health Sciences, LP | 54,658,680 5.800% |
54,658,680 (New Position) |
Filing History |